Chest radiographic finding | Suggested organism |
---|---|
Lobar consolidation | S. pneumoniae, Klebsiella pneumoniae |
Patchy infiltrates | Atypical and fungal organisms |
Interstitial pattern | Mycoplasma or viral organisms |
Miliary pattern | Tuberculosis or fungal organisms |
Apical infiltrate | Tuberculosis |
Infiltrate in superior part of lower lobes or posterior part of the upper lobes | Aspiration pneumonia, anaerobic organisms |
Cavitary lesion | Tuberculosis, S. aureus, anaerobic organisms, Gram-negative bacilli |
Pneumothorax or pneumatocele | Pneumocystis jirovecii |
Critical management
- Provide supplemental oxygen to maintain a saturation higher than 90%.
- Some patients will require mechanical ventilation.
- The evidence for the use of Bi-PAP and CPAP is mixed.
- Noninvasive ventilation should be considered for preoxygenation of hypoxic patients prior to endotracheal intubation.
- Patients who are hypotensive are likely suffering from distributive shock and should be aggressively resuscitated with crystalloids.
- Place patients whose radiograph and history are suggestive of tuberculosis in respiratory isolation.
- All patients with AIDS who have pneumonia should be placed in respiratory isolation because the chest radiograph cannot discriminate between bacterial pneumonia and tuberculosis.
- Two clinical decision rules can assist the physician in deciding whether a patient needs to be admitted for inpatient management, or can be discharged home with outpatient follow-up:
- The Pneumonia Severity Index.
- The CURB-65 rule (Table 54.2). Two or more points warrant hospital admission. Three or more points suggests the need for an ICU admission.
- The Pneumonia Severity Index.
- Initiate appropriate antibiotic therapy.
- CAP; outpatient therapy:
- No comorbidities and no antibiotic use in the past 3 months:
- Macrolides or doxycycline.
- Comorbidities such as diabetes mellitus, asplenism, chronic liver, lung or kidney disease, immunosuppression, alcoholism, malignancy, and patients who have received antibiotics in the last 3 months:
- Respiratory fluoroquinolones or a beta-lactam and a macrolide.
- No comorbidities and no antibiotic use in the past 3 months:
- CAP; inpatient therapy, non-ICU:
- Beta-lactam (ceftriaxone, cefotaxime, ampicillin-sulbactam) and a macrolide or respiratory fluoroquinolone.
- CAP; inpatient therapy, ICU:
- Beta-lactam (ceftriaxone, cefotaxime, ampicillin-sulbactam) and a macrolide or respiratory fluoroquinolone.
- HCAP; inpatient therapy:
- Anti-pseudomonal cephalosporin or anti-pseudomonal carbapenem or piperacillin-tazobactam and
- Anti-pseudomonal fluoroquinolone or aminoglycoside and
- Linezolid or vancomycin to cover MRSA.
- Anti-pseudomonal cephalosporin or anti-pseudomonal carbapenem or piperacillin-tazobactam and
- CAP; outpatient therapy:
- Special situations
- Aspiration pneumonia; add clindamycin or metronidazole.
- AIDS patients with CD4 counts less than 200 cells/microliter should receive coverage for Pneumocystis jirovecii.
- TMP-SMX is the first-line agent.
- Pentamidine can be used in cases of allergy to TMP-SMX.
- Administer steroids if the PaO2 is <70 mmHg or the A-a gradient is >35 mmHg on arterial blood gas analysis.
- TMP-SMX is the first-line agent.
- Aspiration pneumonia; add clindamycin or metronidazole.
Table 54.2. CURB-65 criteria for patients with a diagnosis of pneumonia